LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Company News/Exactech Declares Bankruptcy
Company News

Exactech Declares Bankruptcy

October 31, 2024 4 min read Premium comments

Advertisement

Exactech Declares Bankruptcy
Courtesy of Exactech, Inc.
#bankruptcy#exactech#implantrecall

In a bid to fend off more than 2,200 pending lawsuits, Exactech, Inc.’s owner, TPG Capital, which acquired Exactech in 2018 for $737 million, has decided to put the company into bankruptcy.

While bankruptcy typically spells the end of a company, in this case, it, potentially, gives this venerable orthopedic pioneer a fresh start.

Exactech’s Fight for Survival

Arrayed against Exactech are more than 2,200 pending lawsuits which allege defective implants and injured patients. Approximately 80% of these lawsuits (1,770) are aggregated as a multi-district litigation (MDL) in the U.S. District Court for the Eastern District of New York. The remaining cases are in Florida (595), Illinois (24), and other states (28).

None of these cases have yet been adjudicated. No court has ruled that these claims are true.

Exactech denies the allegations.

The federal courts consolidated the lawsuits into an MDL to reduce costs and streamline the legal process. The MDL includes individual lawsuits, but unlike a class action, the lawsuits can proceed separately.

District Judge Nicholas G. Garaufis, who is overseeing the MDL, has selected four cases for bellwether trials, which are scheduled to begin in 2025.

Advertisement

Exactech’s Product Recall and FDA Warnings

On March 23, 2023, the U.S. Food and Drug Administration (FDA) issued a reminder to surgeons and patients that Exactech’s joint replacement implants manufactured by Exactech between 2004 and August 2021 and recalled in 2021 and 2022 were defective.

According to the FDA, many of Exactech joint replacement devices (including knees, ankles, and hips) were packaged in defective packaging bags. The defective bags were missing one of the oxygen barrier layers that protect devices from oxidation, which is a chemical reaction with oxygen that can degrade plastics over time.

Oxidation can lead to accelerated device wear/failure, and component cracking or fracture, all leading to corrective revision surgery.

The FDA reminded surgeons and patients that Exactech’s recalled devices were associated with increased risk of revision surgeries and bone loss related to excessive device wear/failure.

Exactech began its recall of potentially defective devices in 2021, specifically:

  • In June 2021, Exactech recalled some GXL Liners for Novation, Acumatch, and MCS hip replacement devices due to excessive and premature wear but the root cause was unknown.
  • On February 7, 2022, Exactech expanded the voluntary recall to all Optetrak, Logic, and Truliant knee replacements and Vantage total ankle replacements packaged in defective bags regardless of a device’s label or shelf life. Exactech recalled the devices because around 80% of the knee and ankle replacement devices manufactured since 2004 were packaged in defective bags. Devices packaged in defective bags can lead to oxidation over time that results in the potential risks listed above.
  • In August 2022, Exactech expanded the hip replacement device recall to include all hip devices with polyethylene components packaged in defective bags.

The FDA then issued the following recommendations to surgeons and patients:

  • Do not implant any knee, ankle, and hip devices recalled by Exactech.
  • Do not remove well-functioning Exactech joint replacement devices from patients who do not have any new or worsening pain or symptoms.
  • Monitor patients who have any implanted devices manufactured by Exactech between 2004 and August 2021 for potential device wear, failure, or bone loss. Consider performing X-rays to further evaluate a patient and their implanted device if you suspect a failed device.
  • Discuss revision surgery with patients who may have worsening pain or joint weakness that is potentially attributable to the device based on clinical exam, on a case-by-case basis. As a part of shared decision-making, discuss the benefits and risks of all relevant treatment options with your patients.
  • Remove all recalled devices from inventory and return to Exactech.

How Bankruptcy Will Save Exactech

Advertisement

Exactech, which was founded in 1985, has been one of the most admired and respected orthopedic implant companies in the world. Founded by Bill Petty, M.D., Gary Miller, Ph.D. and Betty Petty, the company developed a reputation as a trusted “surgeon’s company.” In many ways, the company epitomized old fashioned values of integrity, accountability and innovation to serve patients and the surgeons who care for them.

It was a culture that came directly from its founders.

Dr. Petty, specifically, made his early reputation in academic research. Through Exactech and his activities in such organizations as the Orthopedic Research and Education Foundation, he has been a steady champion for improving orthopedics in all its manifestations.

Chapter 11 bankruptcy will allow Exactech to operate as normal, serving orthopedic surgeons and their patients. It relieves Exactech from non-operating legacy liabilities, has brought in new capital ($85 million from an investor group) and will make sure that the plaintiff’s bar doesn’t get between Exactech and its surgeon customers.

According to Exactech’s President and CEO Darin Johnson, “Despite the strength of the underlying business, we face unsustainable liabilities associated with knee and hip litigation related to the packaging recalls we voluntarily initiated between 2021 and 2022. We take our commitment to patient well-being very seriously and have provided substantial out-of-pocket patient reimbursements and surgeon support for related expenses.”

The bankruptcy process, said Johnson, “Is intended to help us create a stronger foundation for long-term growth with an improved balance sheet and new capital as well as ensure that we can continue providing innovative, industry-leading implants for surgeons and their patients for years to come.”

Final Observation

One of the goals of the plaintiff’s bar in these types of litigation is to overwhelm the target company and force it into settlement talks—and to do so, if possible, BEFORE the cases are tried in court. In past cases of mass tort litigation—the breast implant cases or the pedicle screw litigation cases—the plaintiff’s allegations ultimately proved to be either wrong or vastly overstated.

Advertisement

Exactech lives to fight another day. Which is essential for all of orthopedics.

For more information about past mass tort litigation efforts see OTW’s “Biggest Lawsuit in Spine History: The Pedicle Screw Litigation Part I” and “Biggest Lawsuit in Spine History: Pedicle Screw Litigation Part II.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy